Goldman Sachs’s Cognition Therapeutics CGTX Stock Holding History

Goldman Sachs’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,635	Closed	-$4.53K	–	6364
2025 Q2	$4.53K	Buy	+14,635	New	+$4.94K	﹤0.01%	6023

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return

Goldman Sachs's CGTX Position: Q3 2025 in Review

Goldman Sachs sold out of Cognition Therapeutics (CGTX) in Q3 2025, closing a stake of 14,635 shares — an estimated $4.53K sold.

Goldman Sachs first reported a position in CGTX in Q2 2025 and held it in 1 quarter. The position peaked at $4.53K in Q2 2025. 69 funds tracked by Wall St. Rank hold CGTX as of Q3 2025.

Goldman Sachs reported no remaining Cognition Therapeutics position as of Q3 2025 after selling out during the quarter.
Goldman Sachs sold 14,635 Cognition Therapeutics shares in Q3 2025, an estimated $4.53K.
Goldman Sachs first reported a position in Cognition Therapeutics in Q2 2025 and held it in 1 quarter.
Goldman Sachs's Cognition Therapeutics position peaked at $4.53K in Q2 2025.
69 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.